Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Thickeners and Stabilizers
Parenteral
API Stability Enhancers
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Regulatory FDF Prices
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Annual Reports
Main Therapeutic Indication : Dermatology
Currency : USD
2017 Revenue in Millions : 122
2016 Revenue in Millions : 134
Growth (%) : -9
Main Therapeutic Indication : Dermatology
Currency : USD
2018 Revenue in Millions : 128
2017 Revenue in Millions : 122
Growth (%) : 5%
Main Therapeutic Indication : Dermatology
Currency : USD
2016 Revenue in Millions : 134
2015 Revenue in Millions : 138
Growth (%) : -3
Main Therapeutic Indication : Dermatology
Currency : USD
2019 Revenue in Millions : 153
2018 Revenue in Millions : 128
Growth (%) : 19
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
APIs
Reply
03 Nov 2025
Reply
19 Jan 2024
Reply
23 Aug 2023
Reply
23 Aug 2022
Reply
18 Jun 2022
Reply
29 Dec 2021
Reply
07 Oct 2021
Reply
10 Feb 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
12
PharmaCompass offers a list of Ceftaroline Fosamil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ceftaroline Fosamil manufacturer or Ceftaroline Fosamil supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ceftaroline Fosamil manufacturer or Ceftaroline Fosamil supplier.
A TEFLARO manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of TEFLARO, including repackagers and relabelers. The FDA regulates TEFLARO manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. TEFLARO API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of TEFLARO manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A TEFLARO supplier is an individual or a company that provides TEFLARO active pharmaceutical ingredient (API) or TEFLARO finished formulations upon request. The TEFLARO suppliers may include TEFLARO API manufacturers, exporters, distributors and traders.
click here to find a list of TEFLARO suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A TEFLARO DMF (Drug Master File) is a document detailing the whole manufacturing process of TEFLARO active pharmaceutical ingredient (API) in detail. Different forms of TEFLARO DMFs exist exist since differing nations have different regulations, such as TEFLARO USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A TEFLARO DMF submitted to regulatory agencies in the US is known as a USDMF. TEFLARO USDMF includes data on TEFLARO's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The TEFLARO USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of TEFLARO suppliers with USDMF on PharmaCompass.
TEFLARO Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of TEFLARO GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right TEFLARO GMP manufacturer or TEFLARO GMP API supplier for your needs.
A TEFLARO CoA (Certificate of Analysis) is a formal document that attests to TEFLARO's compliance with TEFLARO specifications and serves as a tool for batch-level quality control.
TEFLARO CoA mostly includes findings from lab analyses of a specific batch. For each TEFLARO CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
TEFLARO may be tested according to a variety of international standards, such as European Pharmacopoeia (TEFLARO EP), TEFLARO JP (Japanese Pharmacopeia) and the US Pharmacopoeia (TEFLARO USP).
Comment (4)
